Anti-Treslin, clone 5L19 ZooMAb+ Rab

Application

Anti-Treslin, clone 5L19 ZooMAb, Cat. No. ZRB1063, is a recombinant Rabbit monoclonal antibody that specifically targets Treslin and is tested for use in Affinity Binding Assay, Immunocytochemistry, and Western Blotting.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected Treslin in NIH 3T3 cells. Affinity Binding Assay: A representative lot of this antibody bound Treslin peptides with a KD of 4.3 x 10-6 in an affinity binding assay.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

KLH-conjugated linear peptide corresponding to 25 amino acids from the C-terminal region of human Treslin.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 5L19 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects Treslin. It targets an epitope within 25 amino acids from the C-terminal region.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Treslin (UniProt: Q7Z2Z1; also known as TopBP1-interacting checkpoint and replication regulator, TopBP1-interacting, replication-stimulating protein) is encoded by the TICRR (also known as C15orf42) gene (Gene ID: 90381) in human. Treslin is a well conserved nuclear protein that associates with replicating chromatin. It serves as a regulator of DNA replication by promoting integration of Cdc45 into the replicative helicase. It is a key positive-regulatory target of cell-cycle control mechanisms and activation of Treslin by cyclin-dependent kinase (CDK) is shown to be essential for the initiation of replication. It possesses an unusually large number of potential CDK phosphorylation sites. Checkpoint-regulatory kinase Chk1 is shown to associate with a C-terminal domain of Treslin (TRCT) and mutations in the TRCT domain are known to abolish binding of Chk1 to Treslin and thereby eliminate its phosphorylation by Chk1. Disruption of the Treslin-Chk1 interaction is shown to increase initiation of chromosomal DNA replication. Two isoforms of Treslin have been described that are produced by alternative splicing. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Kumagai, A., et al. (2010). Cell. 140(3); 349-359; Guo, C., et al. (2015). Mol. Cell. 57(3); 492-505).